7:50 am
Chairperson’s Opening Remarks

Reducing Toxicity to Widen the Therapeutic Index of Your Cytokine

8:00 am Avoiding Cytokine Storm With Novel Cytokine- & Cell-Directed Therapies


  • Identify key features of cytokine release and cell-directed therapy which should be monitored short- and long-term in patients
  • Understand the importance of cytokine and immune cell subset dynamics and timing of treatment in order to modulate patient outcomes
  • Combination chemo-immunotherapy – explore the potential for logical sequenced treatment

8:30 am NT-I7, a Long-acting IL-7, as a New Promise to Increase CAR-T Efficacy Without Risking CRS

  • Byung Ha Lee Senior Vice President & Chief Scientific Officer, NeoImmuneTech Inc.


  • Evaluating the effect of NT-I7, a long-acting IL-7, and CAR-T combination: pre-clinical data
  • Analyzing the effect of NT-I7 on CAR-T expansion and persistence: preliminary clinical data
  • Reviewing the effect of NT-I7 on CAR-T safety: preliminary clinical data

9:00 am Panel Discussion: : Understanding Cytokine Release Syndrome to Overcome Issues With Toxicities in Your Drug


  • Characterizing cytokine release syndrome
  • Overcoming mischaracterizing of cytokine release syndrome
  • How to sensitize the patients and public to cytokine release syndrome

9:40 am Speed Networking & Morning Coffee Break


Join us for face-to-face networking. We will pair you up with fellow attendees so you can get one on one time with the brightest minds working in the cytokine field and establish meaningful relationships.

Optimizing In Vitro Assays to Improve Understanding of Cytokine Mode of Action

10:40 am Understanding Clustering in the TNFR for the Better Design of Therapeutics


  • Assessing the TNF superfamily mechanism of action
  • Discussing the benefits of clustering in receptors
  • Highlighting the targeted design of better agonists and antagonists

11:10 am Tools for Cytokine Therapeutic Development – From Discovery to Lot Release

  • Jeff Nelson Product Manager - Biologics, Promega Corporation


  • Learn how cell-based reporter bioassays are used in the development of therapeutic cytokines to confirm mechanism of action and measure drug potency and stability
  • Discover a convenient thaw-and-use assay format that saves time and provides reproducible results across laboratories
  • Hear about a novel immunoassay technology (LumitTM) that provides a simple, sensitive and rapid alternative to ELISA detection of cytokine release 

11:40 am Lunch Break

Overcoming Challenges with Preclinical Models to Ensure Optimized Translation into the Clinic

12:40 pm Leveraging Preclinical Models to Get the Best Preclinical Insights


  • Reviewing the current state of animal models
  • Identifying the right model for the right question
  • How development of better animal systems may aid in translation

1:10 pm Title-Key Considerations When Choosing Recombinant Proteins for Cell and Gene Therapy Applications

  • Samuel Molina Director - Shenandoah Biotechnology & Research Development, FUJIFILM Irvine Scientific


  • Interleukins (ILs): The role they play in the regulation of adaptive cellular response
  • Critical factors when selecting a supplier for your recombinant proteins
  • Developing recombinant growth factors and cytokines for cell-based therapies
  • Achieving optimal results through a scientifically-driven selection of products
  • Why a close partnership with your supplier can accelerate the development process to therapy 

1:40 pm Developing NT-I7, a Long-acting IL-7, for Acute Radiation Syndrome Under the Animal Rule


  • Examine the introduction of the FDA’s Animal Rule and its opportunity for cytokine drug development
  • Assess acute radiation syndrome (ARS) and cytokines that have been approved for ARS under the animal rule, followed by the rationale of pursuing ARS with NT-I7
  • Evaluate a summary of preclinical data generated testing NT-I7 in the murine ARS model and next steps

2:10 pm Optimizing Preclinical Models to Fully Represent the Clinic & Translational Work


  • How to design accurate models
  • Improving preclinical models to measure the response accurately
  • Developing your models to accurately represent the clinic

2:40 pm Scientific Poster Session


After the formal presentations have finished, the scientific Poster Session is an informal part of the conference agenda, allowing you to connect with your peers in a relaxed atmosphere. Continue to forge new and cement existing relationships while learning about the latest developments and breakthroughs in this field.

Exploring Cytokines Beyond Oncology to Widen the Therapeutic Application of Cytokines

3:10 pm Structure-guided Engineering of Treg-promoting Cytokine Fusion Proteins to Treat Autoimmune Diseases

  • Jamie Spangler Assistant Professor - Biomedical Chemical & Biomolecular Engineering, Johns Hopkins


  • Understand how Cytokine/antibody fusion proteins (immunocytokines) selectively deliver cytokines to particular immune cell subsets through distinctive structural and molecular effects
  • Discover how Immunocytokines prevent the development of autoimmune diseases in mice
  • Learn how optimization of cytokine/antibody affinity enables development of immunocytokines with tunable immune biases

3:40 pm Understanding Novel Cytokine-Based Virotherapies to Treat Infectious Diseases


  • Viral vectors are a potent delivery platform largely used to develop prophylactic and therapeutic vaccines
  • The genome plasticity of the MVA and its capacity to stimulate innate immunity was exploited to deliver a cytokine engaging pathways of the adaptive immunity
  • Additional cytokine encoding MVAs have confirmed the value of this platform in treatment of candida infections 

4:10 pm Panel Discussion: : Examining the Possible Applications of Non-Oncology Cytokine Based Drugs to Turbocharge Development in the Field

  • Eva Vanamee CSO, FusionBio, Inc.
  • Jamie Spangler Assistant Professor - Biomedical Chemical & Biomolecular Engineering, Johns Hopkins


  • How can research on cytokines used in the non-oncology field be used to optimize the research in oncology?
  • Is the research translatable and can it be used in both the fields?
  • Exploring the reverse – can cytokine-based drugs in oncology have non-oncology applications?

4:50 pm
Chairperson’s Closing Remarks

5:00 pm End of Scientific Day One